Triple-Threat drug attack tested against aggressive blood cancer
NCT ID NCT07407140
Summary
This study is testing whether a new combination of three targeted drugs works better than standard chemotherapy for adults with a specific genetic type of acute myeloid leukemia (AML). About 300 newly diagnosed patients with an FLT3 gene mutation will receive either the new drug combo or standard chemo, plus a targeted drug called gilteritinib. The main goal is to see which treatment keeps patients in remission longer and improves survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.